Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study

Detalhes bibliográficos
Autor(a) principal: Celum, Connie
Data de Publicação: 2017
Outros Autores: Hong, Ting, Cent, Anne, Donnell, Deborah, Morrow, Rhoda, Baeten, Jared M., Firnhaber, Cynthia, Grinsztejn, Beatriz, Hosseinipour, Mina C., Lalloo, Umesh, Nyirenda, Mulinda, Riviere, Cynthia, Sanchez, Jorge, Santos, Breno, Supparatpinyo, Khuanchai, Hakim, James, Kumarasamy, N., Campbell, Thomas B., ACTG PEARLS/A5175 Team
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/34394
Resumo: 2020-07-24
id CRUZ_2b64caa31d1ed88a3155eab11cce568e
oai_identifier_str oai:www.arca.fiocruz.br:icict/34394
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Celum, ConnieHong, TingCent, AnneDonnell, DeborahMorrow, RhodaBaeten, Jared M.Firnhaber, CynthiaGrinsztejn, BeatrizHosseinipour, Mina C.Lalloo, UmeshNyirenda, MulindaRiviere, CynthiaSanchez, JorgeSantos, BrenoSupparatpinyo, KhuanchaiHakim, JamesKumarasamy, N.Campbell, Thomas B.ACTG PEARLS/A5175 Team2019-07-24T14:27:52Z2019-07-24T14:27:52Z2017CELUM, Connie et al. Herpes simplex virus type 2 acquisition among HIV-1- infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTGA5175 PEARLS Study. Journal of Infectious Diseases, v. 215, p. 907-910, 2017.1413-8670https://www.arca.fiocruz.br/handle/icict/3439410.1093/infdis/jix0291678-4391engElsevierHerpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article2020-07-24University of Washington. Department of Global Health. Seattle, WA, USA / University of Washington. Department of Medicine. Seattle, WA, USA / University of Washington. Department of Epidemiology. Seattle, WA, USA.University of Washington. Department of Global Health. Seattle, WA, USAUniversity of Washington. Laboratory Medicine. Seattle, WA, USA.University of Washington. Department of Global Health. Seattle, WA, USA / Fred Hutchinson Cancer Research Center. Seattle, WA, USA.University of Washington. Laboratory Medicine. Seattle, WA, USA / Fred Hutchinson Cancer Research Center. Seattle, WA, USA.University of Washington. Department of Global Health. Seattle, WA, USA / University of Washington. Department of Medicine. Seattle, WA, USA / University of Washington. Department of Epidemiology. Seattle, WA, USA.University of the Witwatersrand. Faculty of Health Sciences. Department of Medicine. Clinical HIV Research Unit. Johannesburg, South Africa.Fundação Oswaldo Cruz. Instituto de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.Kamuzu Central Hospital. Lilongwe, Malawi.Nelson R. Mandela School of Medicine. Durban, South Africa.College of Medicine. Department of Medicine. Blantyre, Malawi.Institut Nacional de laboratoire et de Recherches. Port-au-Prince, Haiti.Asociación Civil Impacta Salud y Educación, Lima, Peru.Grupo Hospitalar Conceição. Hospital Nossa Senhora da Conceição. Serviço de Infectology. Porto Alegre, RS, Brazil.Chiang Mai University. Department of Medicine. Thailand / Chiang Mai University. Research Institute for Health Sciences. ThailandUniversity of Zimbabwe. College of Health Sciences, Harare.YRG Centre for AIDS Research and Education, Chennai, India.University of Colorado. School of Medicine. Department of Medicine. Aurora, CO, USA.Objective. Tenofovir disoproxyl fumarate (TDF) disoproxyl fumarate (TDF) has in vitro activity against herpes simplex virus type 2 (HSV-2) and reduced HSV-2 acquisition as preexposure prophylaxis. Whether TDF-containing antiretroviral therapy (ART) reduces HSV-2 acquisition is unknown. Design. Secondary analysis of AIDS Clinical Trials Group A5175, a randomized, open-label study of 3 ART regimens among 1571 participants. Methods. HSV-2 serostatus was assessed at baseline, at study exit, and before a change in ART regimen. Results. Of 365 HSV-2–seronegative persons, 68 acquired HSV-2, with 24 receiving TDF-containing ART and 44 receiving ART without TDF (HSV-2 seroconversion incidence, 6.42 and 6.63 cases/100 person-years, respectively; hazard ratio, 0.89; 95% confidence interval, .55–1.44). Conclusions. HSV-2 acquisition was not reduced in HIVinfected, HSV-2–uninfected persons during TDF-containing ART.HIV-1HSV-2PreventionTenofovirAntiretroviral therapyAfricainfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83104https://www.arca.fiocruz.br/bitstream/icict/34394/1/license.txt79178e5f2a0eb066867a274556814938MD51ORIGINALve_Celum_Connie_etal_INI_2017.pdfve_Celum_Connie_etal_INI_2017.pdfapplication/pdf332833https://www.arca.fiocruz.br/bitstream/icict/34394/2/ve_Celum_Connie_etal_INI_2017.pdffe265bfe4c98d45f96d2dc3d58207351MD52TEXTve_Celum_Connie_etal_INI_2017.pdf.txtve_Celum_Connie_etal_INI_2017.pdf.txtExtracted texttext/plain23970https://www.arca.fiocruz.br/bitstream/icict/34394/3/ve_Celum_Connie_etal_INI_2017.pdf.txtddabcbf13bf28113fd0f22f97ac521acMD53icict/343942021-03-24 16:32:34.578oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-03-24T19:32:34Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study
title Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study
spellingShingle Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study
Celum, Connie
HIV-1
HSV-2
Prevention
Tenofovir
Antiretroviral therapy
Africa
title_short Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study
title_full Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study
title_fullStr Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study
title_full_unstemmed Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study
title_sort Herpes simplex virus type 2 acquisition among HIV-1-infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTG A5175 PEARLS study
author Celum, Connie
author_facet Celum, Connie
Hong, Ting
Cent, Anne
Donnell, Deborah
Morrow, Rhoda
Baeten, Jared M.
Firnhaber, Cynthia
Grinsztejn, Beatriz
Hosseinipour, Mina C.
Lalloo, Umesh
Nyirenda, Mulinda
Riviere, Cynthia
Sanchez, Jorge
Santos, Breno
Supparatpinyo, Khuanchai
Hakim, James
Kumarasamy, N.
Campbell, Thomas B.
ACTG PEARLS/A5175 Team
author_role author
author2 Hong, Ting
Cent, Anne
Donnell, Deborah
Morrow, Rhoda
Baeten, Jared M.
Firnhaber, Cynthia
Grinsztejn, Beatriz
Hosseinipour, Mina C.
Lalloo, Umesh
Nyirenda, Mulinda
Riviere, Cynthia
Sanchez, Jorge
Santos, Breno
Supparatpinyo, Khuanchai
Hakim, James
Kumarasamy, N.
Campbell, Thomas B.
ACTG PEARLS/A5175 Team
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Celum, Connie
Hong, Ting
Cent, Anne
Donnell, Deborah
Morrow, Rhoda
Baeten, Jared M.
Firnhaber, Cynthia
Grinsztejn, Beatriz
Hosseinipour, Mina C.
Lalloo, Umesh
Nyirenda, Mulinda
Riviere, Cynthia
Sanchez, Jorge
Santos, Breno
Supparatpinyo, Khuanchai
Hakim, James
Kumarasamy, N.
Campbell, Thomas B.
ACTG PEARLS/A5175 Team
dc.subject.en.pt_BR.fl_str_mv HIV-1
HSV-2
Prevention
Tenofovir
Antiretroviral therapy
Africa
topic HIV-1
HSV-2
Prevention
Tenofovir
Antiretroviral therapy
Africa
description 2020-07-24
publishDate 2017
dc.date.issued.fl_str_mv 2017
dc.date.accessioned.fl_str_mv 2019-07-24T14:27:52Z
dc.date.available.fl_str_mv 2019-07-24T14:27:52Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv CELUM, Connie et al. Herpes simplex virus type 2 acquisition among HIV-1- infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTGA5175 PEARLS Study. Journal of Infectious Diseases, v. 215, p. 907-910, 2017.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/34394
dc.identifier.issn.pt_BR.fl_str_mv 1413-8670
dc.identifier.doi.none.fl_str_mv 10.1093/infdis/jix029
dc.identifier.eissn.none.fl_str_mv 1678-4391
identifier_str_mv CELUM, Connie et al. Herpes simplex virus type 2 acquisition among HIV-1- infected adults treated with tenofovir disoproxyl fumarate as part of combination antiretroviral therapy: results from the ACTGA5175 PEARLS Study. Journal of Infectious Diseases, v. 215, p. 907-910, 2017.
1413-8670
10.1093/infdis/jix029
1678-4391
url https://www.arca.fiocruz.br/handle/icict/34394
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/34394/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/34394/2/ve_Celum_Connie_etal_INI_2017.pdf
https://www.arca.fiocruz.br/bitstream/icict/34394/3/ve_Celum_Connie_etal_INI_2017.pdf.txt
bitstream.checksum.fl_str_mv 79178e5f2a0eb066867a274556814938
fe265bfe4c98d45f96d2dc3d58207351
ddabcbf13bf28113fd0f22f97ac521ac
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324662956982272

Registros relacionados